MwanzoSGEN • BMV
add
Seagen
Bei iliyotangulia
$ 3,711.48
Bei za mwaka
$ 3,711.48 - $ 3,711.48
Thamani ya kampuni katika soko
43.15B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 648.65M | 27.11% |
Matumizi ya uendeshaji wa biashara | 262.69M | 24.86% |
Mapato halisi | -215.79M | -13.09% |
Kiwango cha faida halisi | -33.27 | 11.02% |
Mapato kwa kila hisa | -1.15 | -11.65% |
EBITDA | -209.33M | -19.47% |
Asilimia ya kodi ya mapato | 0.26% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 1.24B | -29.86% |
Jumla ya mali | 3.63B | 0.42% |
Jumla ya dhima | 1.08B | 35.94% |
Jumla ya hisa | 2.55B | — |
hisa zilizosalia | 188.66M | — |
Uwiano wa bei na thamani | 274.52 | — |
Faida inayotokana na mali | -16.01% | — |
Faida inayotokana mtaji | -21.12% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2023info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -215.79M | -13.09% |
Pesa kutokana na shughuli | -35.82M | 58.21% |
Pesa kutokana na uwekezaji | 142.49M | 119.31% |
Pesa kutokana na ufadhili | 15.52M | -15.59% |
Mabadiliko halisi ya pesa taslimu | 119.90M | 1,958.05% |
Mtiririko huru wa pesa | 71.52M | 1,141.10% |
Kuhusu
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
15 Jul 1997
Makao Makuu
Tovuti
Wafanyakazi
3,256